<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640289</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IND5986</org_study_id>
    <nct_id>NCT00640289</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Factor XIII (FXIII) Concentrate</brief_title>
  <official_title>Clinical Research Study of Factor XIII Concentrate From Human Plasma Fibrogammin P in Patients With Factor XIII Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children’s Hospital of Orange County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children’s Hospital of Orange County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital deficiency of Factor XIII is a rare but potentially life threatening disorder. It
      is inherited in an autosomal recessive fashion. Infusion of Factor XIII has proved to be
      useful for prevention and treatment of bleeding episodes, especially of spontaneous
      intracranial bleedings. In this study, Fibrogammin P will be given to patients with
      congenital Factor XIII deficiency and congenital/acquired FXIII deficiency to prevent
      bleeding and to treat established bleeding episodes. For Factor XIII prophylaxis to prevent
      hemorrhages, the dosage will depend on the weight of the subject. The frequency of Factor
      XIII administration will be determined by the factor's circulating half-life. During the
      first month only, a Factor XIII pharmacokinetic study will be determined over a 4-week
      period. Safety data will include accrual of information on viral safety, liver function,
      complete blood counts and adverse events. Historical data concerning spontaneous bleeds will
      be collected whenever possible two years prior to treatment with Fibrogammin P.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment. Active bleeding is controlled.</measure>
    <time_frame>Within 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal to no bleeding with surgery following prophylactic treatment.</measure>
    <time_frame>During surgery.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hemophilia</condition>
  <condition>Factor XIII Deficiency</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrogammin P</intervention_name>
    <description>Prophylaxis treatment</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients may be of either sex or age. Children and newborn infants are specifically
             included in this study.

          -  Patient must have documented congenital Factor XIII deficiency

          -  Patient or legal guardian must sign informed consent

          -  Patients who have negative serology for hepatitis B should receive Hepatitis B
             vaccination.

        Exclusion Criteria:

          -  Patient has acquired Factor XIII deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane J. Nugent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Orange Co.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange Co.</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children’s Hospital of Orange County</investigator_affiliation>
    <investigator_full_name>Diane J. Nugent, MD</investigator_full_name>
    <investigator_title>Director Hemostasis/Thrombosis Research</investigator_title>
  </responsible_party>
  <keyword>Factor XIII Deficiency</keyword>
  <keyword>Rare Bleeding Disorder</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>Fibrogammin P</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Factor XIII Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

